MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease

S. Rajput, S. Sinha (New Delhi, India)

Meeting: 2019 International Congress

Abstract Number: 1466

Keywords: Behavioral abnormalities, Drug-induced parkinsonism(DIP), Oxidative stress

Session Information

Date: Tuesday, September 24, 2019

Session Title: Drug-Induced Movement Disorders

Session Time: 1:45pm-3:15pm

Location: Agora 2 West, Level 2

Objective: Objective of our study was to evaluate protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease.

Background: Parkinson’s disease (PD), an age-related disorder, is accompanied by the symptoms, tremor, bradykinesia, rigidity and instability. Cinnamaldehyde (CA) is a diterpene with a wide range of anti-inflammatory, cognitive enhancer, neuroprotective effects thus may be advantageous in the treatment of neurological disease.

Method: In present study  6-hydroxydopamine (6-OHDA) model of PD mice were used. The symptoms of PD such as tremors, akinesia, rigidity, catalepsy, and vacuous chewing movements (VCMs) were evaluated. The methanolic extract of  CA was administered orally at doses of 100 mg, 200 mg and 500 mg/kg body weight followed by stress. The combination of L-dopa and carbidopa was used as a standard drug. Behavioral studies such as locomotor activity and grip strength were determined, and memory test (Morris water maze) was evaluated in mice. Reactive oxygen species (ROS) generation was measured using dihydroethidium (DHE) staining. Antioxidants enzymes, neurolipofusicin, lipid peroxides and  inflammatory cytokines (TNF-a, IL-1β, and IL-6) were measured in hippocampus using corresponding commercial kits were analyzed in rat model of PD.

Results: Animal exposed to stress showed significant decrease in antioxidant enzyme,   glutathione and total protein. This was accompanied by simultaneous increase in lipid peroxides and neurolipofusicin level. Treatment with CA had no significant but moderate effect on antioxidant enzyme. Pretreatment with CA (200 and 500 mg/kg) significantly reduced the intensity of muscular rigidity, duration of catalepsy, akinesia, the number of tremors, and significantly increased locomotor activity and grip strength.  Treatment with CA significantly reduced inflammatory cytokines , ROS level,  lipid peroxides level and restored the defensive antioxidant enzymes in mice brain.

Conclusion: CA may extract appreciably improve the neuroinflammatory processes and also restore biochemical and behavioral parameters with a potential therapeutic candidate for anti-aging studies.

To cite this abstract in AMA style:

S. Rajput, S. Sinha. Protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/protective-and-therapeutic-activity-of-cinnamaldehyde-in-the-mouse-model-of-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/protective-and-therapeutic-activity-of-cinnamaldehyde-in-the-mouse-model-of-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley